Live·Open questions in longevity research
All news
Industry & policyBiotech fundingLongevity research

FDA adds aging to the research areas it is prepared to fund in fiscal year 2027

19 November 2026· 261119008

FDA adds aging to the research areas it is prepared to fund in fiscal year 2027

On October 30, FDA posted an open call on the federal procurement portal SAM.gov for regulatory science research, which develops tools and standards for evaluating product safety and effectiveness. “Aging and longevity” is the tenth of 22 research areas in the call and applies only to drugs. Proposals for fiscal year 2027 are due by January 22.

FDA evaluates a drug against a prespecified trial outcome, known as an endpoint, such as fewer heart attacks or longer survival. Sometimes FDA accepts a measurable indicator that predicts the outcome, called a surrogate endpoint, which allows a shorter trial. For example, lower blood pressure predicts fewer strokes, and drugs have been approved on that basis.

The BEST glossary, jointly developed by FDA and the US National Institutes of Health, defines a surrogate endpoint as “validated” when convincing evidence shows that a change in the indicator predicts benefit, and as “reasonably likely” when the rationale is strong but the evidence is limited. According to the summary of the Reagan-Udall Foundation meeting on May 27, FDA Chief Scientist Steven Kozlowski noted that no intervention has been approved for an indication of “aging,” and no aging biomarker (a measurable indicator of biological age) has been recognized as a validated or reasonably likely surrogate endpoint.

The call is a Broad Agency Announcement, or BAA: FDA lists its research needs, universities and companies submit proposals, and successful applicants receive funding through contracts. According to FDA, the overall call received 228 proposals in fiscal year 2026, resulting in 53 contracts and 63,6 million dollars in funding. The 2026 announcement had no separate topic on aging.

The aging section has three parts. The first covers tools for assessing physical and cognitive function and age-related outcomes, including walking speed, grip strength, cognitive tests, and “disability-free survival.” It also covers trial designs that combine several events into a single outcome: cardiovascular disease, cancer, dementia, death, and functional decline. The second covers molecular biomarkers, cellular and computational models to replace some animal experiments, and validation of aging biomarkers. The third covers observations over time: how function changes and how biomarkers relate to subsequent outcomes. In May, Kozlowski emphasized that molecular biomarkers are useful for research, while functional outcomes more closely reflect patient benefit. The announcement calls for research on both.

The announcement names epigenetic clocks among the biomarkers to be evaluated. These are algorithms that estimate biological age from chemical marks on DNA. The aim is to move biomarkers closer to recognition as validated or “reasonably likely” surrogate endpoints. A review of 26 studies using epigenetic clocks found none that used data from multiple trials to test whether changes in clock readings predict the benefit of an intervention.

At the ARDD aging research conference in early October, Kozlowski described the endpoint he would like to see:

“It would be very useful to have a shared endpoint, developed precompetitively, qualified, and available to everyone, so that anyone could use it as a bridge.”

He said it should be accepted by the regulator, make trials feasible, and serve as a standard for everything new that follows.

FDA may consider proposals submitted after the deadline but before September 21, 2027, for fiscal year 2028. On December 8, FDA will hold an open online meeting about the call.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#fda#aging-biomarkers#surrogate-endpoints#epigenetic-clocks#regulatory-science#fiscal-year-2027